Rat liver transport and biotransformation of a cytostatic complex of bis-cholylglycinate and platinum (II)

Journal of Hepatology

Volumn 28, Issue 3, 1998, Pages 417-425

  Marin, Jose J g ^a   Herrera, Maria C ^a   Palomero, Maria F ^a   MacIas, Rocio I r ^a   Monte, Maria J ^a   El Mir, Mohamed Y ^a   Villanueva, Gloria R ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Bile acid; Cancer; Chemotherapy; Glycocholate; Hepatocyte; Metal; Tumor

Indexed keywords

BAMET H2; BILE ACID; CHOLIC ACID DERIVATIVE; CHOLINE; CISPLATIN; CYTOSTATIC AGENT; GLYCOCHOLIC ACID; PLATINUM DERIVATIVE; SODIUM ION; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BILE FLOW; CELL TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG TRANSFORMATION; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRCULATION; LIVER SINUSOID; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0032032526     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80315-2     Document Type: Article

References (28)

1. Ho NFH. Utilizing bile acid carrier mechanisms to enhance liver and small intestine absorption. Ann NY Acad Sci. 907:1987;315-329.
2. Betebenner DA, Carney PL, Zimmer AM, Kazikiewicz JM. Hepatobiliary delivery of polyaminopolycarboxylate chelate: synthesis and characterization of a cholic acid conjugate of EDTA and biodistribution and imaging studies with its indium-111 chelate. Bioconjug Chem. 2:1991;117-123.
3. Stephan ZF, Yurachek EC, Sharif R, Wasvary JM, Steele RE, Howes C. Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. Biochem Pharmacol. 43:1992;1969-1974.
4. Kramer W, Wess G. Bile acid transport systems as pharmaceutical targets. Eur J Clin Invest. 26:1996;715-732.
5. Meijer DKF. Drug targeting to the liver with bile acids - the Trojan horse resurrected. Hepatology. 17:1993;945-948.
6. Kroker R, Anwer MS, Hegner D. The lack of active bile acid transport in AS-30D ascites hepatoma cells. Naunyn Schmiedeberg Arch Pharmacol. 303:1978;299-301.
7. Von Dippe P, Levy D. Expression of the bile acid transport protein during liver development and in hepatoma cells. J Biol Chem. 265:1990;5942-5945.
8. Marchegiano P, Carubbi F, Tiribelli C, Amarri S, Stebel M, Lunazzi GC, et al. Transport of sulfobromophthalein and taurocholate in the HepG2 cell line in relation to the expression of membrane carrier proteins. Biochem Biophys Res Commun. 183:1992;1203-1208.
9. Kullak-Ublick GA, Beuers U, Paumgartner G. Molecular and functional characterization of bile acid transport in human hepatoblastoma HepG2 cells. Hepatology. 23:1996;1053-1060.
10. Criado JJ, Herrera MC, Palomero MF, Medarde M, Rodriguez E, Marin JJG. Synthesis and characterization of a new bile acid and platinum (II) complex with cytostatic activity. J Lipid Res. 38:1997;1022-1032.
11. Marin JJG, Criado JJ, Palomero MF, Herrera MC, Macias RIR, Monte MJ, et al. Platinated bile acids as cytostatic drugs [abstract]. Hepatology. 24:1996;542.
12. Loeher PJ, Einhorn LH. Cisplatin. Ann Intern Med. 100:1984;704-713.
13. Bradner WT, Rose WC, Huftalen JB, Carter SK. Antitumor activity of platinum analogs. Prestayko AW, Crooke ST. Cisplatin: Current Status and New Developments. 1980;171-182 Academic Press, New York.
14. Christian MC. The current status of new platinum analogs. Semin Oncol. 19:1992;720-733.
15. Maeda M, Takasuka N, Suga T, Sasaki T. New antitumor platinum (II)_complexes with both lipophilicity and water miscibility. Jpn J Cancer Res. 81:1990;567-569.
16. Maeda M, Suga T, Takasuda N, Hoshi A, Sasaki T. Effect of bis(bilato)-1,2-cyclohexanediammine platinum (II) complexes on lung metastasis of B16-F10 melanoma cells in mice. Cancer Lett. 55:1990;143-147.
17. Marin JJG, Herrera MC, Palomero MF, Macias RIR, Monte MJ, Villanueva GR, et al. In vivo distribution, toxicity and cytostatic capacity of platinated bile acid analogs [abstract]. Hepatology. 24:1996;372.
18. Hofmann AF. Biliary secretion and excretion - the hepatobiliary component of the enterohepatic circulation of bile acids. Johnson LR. Physiology of the Gastrointestinal Tract. 1994;1555-1576 Raven Press, New York.
19. Berry MN, Edwards AM, Barritt GJ. Isolated Hepatocytes. Preparation, Properties and Applications. 1991;Elsevier, Amsterdam.
20. + -taurocholate cotransport and its encoding messenger RNA in primary cultures of rat hepatocytes. Hepatology. 18:1993;1162-1166.
21. Marin JJG, Esteller A, Villanueva GR. Diabetes-induced cholestasis in the rat. Possible role of hyperglycemia and hypoinsulinemia. Hepatology. 8:1988;332-340.
22. Miller LL, Bly CG, Watson ML, Bale WF. The dominant role of the liver in plasma protein synthesis. J Exp Med. 94:1951;431-445.
23. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 87:1978;206-210.
24. Kramer W, Wess G, Schubert G, Bickel M, Hoffmann A, Baringhaus KH, et al. Bile acids as carrier for drugs. Paumgartner G, Stiehl A, Gerok W. Bile Acids and the Hepatobiliary System. From the Basic Science to the Clinical Practice. 1993;161-176 Kluwer Academic Publishers, Dordrecht, The Netherlands.
25. Chu G. Cellular responses to cisplatin - the roles of DNA-binding proteins and DNA repair. J Biol Chem. 269:1994;787-790.
26. Gatmaitan ZC, Arias IM. ATP-dependent transport systems in the canalicular membrane of the hepatocyte. Physiol Rev. 75:1995;261-275.
27. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56:1996;4124-4129.
28. Mazzanti R, Fantappie O, Kamimoto Y, Gatmaitan ZC, Gentilini P, Arias IM. Bile acid inhibition of P-glyco-protein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles. Hepatology. 20:1994;170-176.